Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management

Area of Science:

• Endocrinology
• Cardiology
• Internal Medicine

Background:

• Acromegaly, a rare endocrine disorder, results from excess growth hormone (GH) and insulin-like growth factor-1 (IGF-1).
• Acromegalic cardiomyopathy is a major cause of illness and death in acromegaly patients.
• Pathological changes include myocyte hypertrophy, impaired cardiac contractility, and valvular dysfunction.

Purpose of the Study:

• To review the pathophysiology, diagnosis, and management of acromegalic cardiomyopathy.
• To emphasize the importance of early recognition and treatment for improved patient outcomes.

Main Methods:

• Review of literature on acromegaly and its cardiac manifestations.
• Discussion of diagnostic criteria, including biochemical testing (IGF-1 levels).
• Overview of management strategies, including surgical and medical therapies.

Main Results:

• Elevated GH and IGF-1 levels lead to biventricular hypertrophy and heart dysfunction.
• Biochemical testing with IGF-1 is the standard for diagnosis.
• Normalization of GH and IGF-1 levels is crucial for reducing mortality.

Conclusions:

• Acromegalic cardiomyopathy significantly increases morbidity and mortality.
• Early diagnosis and effective management, primarily by normalizing GH and IGF-1, are essential.
• Transsphenoidal surgery and medical therapies are key treatment options.